Amylyx Pharmaceuticals, Inc. (AMLX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor.
Is Amylyx Pharmaceuticals, Inc. stock overvalued or undervalued in 2026?
As of November 2, 2026, Amylyx Pharmaceuticals, Inc. (AMLX) trades at $28.04 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Amylyx Pharmaceuticals, Inc.
Market cap $4B · 52 weeks $11 – $40 (29 % below the high) · P/E no earnings · Dividend none · Next earnings November 5, 2026 · expected EPS -$0.38 · Closing price, Nov 2 · accounts published Aug 6.
- Valuation: P/E — (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 3 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 8.4×, fails.
- Cash Runway 31 months, passes.
- Total Debt 0.0×, passes.
- Annual cash burn $1.30, info.
Against its peers (reference peers) — Amylyx Pharmaceuticals, Inc.: P/E —; EV/EBITDA —; ROIC -66.3 %; $3.5B. Acadia Pharmaceuticals Inc. (P/E 9.2×; EV/EBITDA 27.7×; ROIC 6.2 %; $3.5B), Arcutis Biotherapeutics, Inc. (P/E 150×; EV/EBITDA 94.7×; ROIC 9.9 %; $3.9B), Telix Pharmaceuticals Limited (P/E 95.0×; EV/EBITDA 113×; ROIC -0.6 %; $3.1B).
Profitability
| Return on Equity | -52.92% |
| Return on Invested Capital | -66.32% |
| Return on Assets | -57.49% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 12.12 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 21.43 |
Price Performance
| 1 month | +0.90% |
| 3 months | +28.33% |
| Year-to-date | +132.12% |
| 1 year | +106.18% |
| 3 years | +52.14% |
Dividend History
| Date | Amount |
|---|---|
| March 28, 2018 | $0.42 |
| December 28, 2017 | $0.36 |
| September 28, 2017 | $0.24 |
Amounts adjusted for stock splits.
Related companies: IONS · PRAX · DNLI · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of AMLX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks